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ABSTRACT
rain Metastases are neoplasms that originate in 
tissues outside the Brain and then spread Bsecondarily to the brain. Brain metastases have 
excited neurological interest since the first case was 
1reported in Schrautin 1853 .It is a devastating 
complication of malignant disease, outnumbering 
2primary Brain tumor by a factor of 10:1.  The exact 
frequency of Brain metastases is difficult to determine 
with precision, but they are estimated to affect 25% of 
3 Cancer patients. In an autopsy series done at the 
University College Hospital Ibadan, the incidence rate 
1for Brain Metastases was 6.4%.
Incidence of Brain Metastases is increasing due to an 
ever increasing ageing population, therapeutic control 
of systemic disease , inability of the drugs to penetrate 
the blood brain barrier, aggressiveness and biology of 
4,5,6the tumor.
Most Brain Metastases originate from Lung (40-50%), 
Breast (15-25%), Melanoma (5-20%) and Kidney (5-
210%). No Tumor of origin /primary site of cancer is 
7detected in 5-10% of patients with Brain Metastases.  
Brain Metastases are suspected in any cancer patient 
who develops any new neurological symptoms. 
Common symptom of Brain Metastases results from 
raised Intracranial Pressure such as headaches, 
6seizures, Vomiting.
MRI has become the standard of care for imaging of the 
Central Nervous System in Cancer Patients.
INTRODUCTION
BACKGROUND
Brain Metastases is a devastating complication of Cancer affecting 10-50% of patients with systemic disease. It by far 
outnumbers primary Brain tumor in a 10:1 ratio.
AIMS AND OBJECTIVE
To determine the age distribution, gender distribution, tumor of origin, commonest radiotherapy regimen and 
median survival of patients who received Whole Brain Radiotherapy for Brain Metastases.
MATERIALS AND METHODS
Between May 2006-May 2015 patients who received Whole Brain Radiotherapy for Brain Metastases for confirmed 
Brain Metastases were studied in a Retrospective study and evaluated with respect to age, gender, tumor of origin 
and radiotherapy regimen. Patients Case files and treatment  files were reviewed and results were analyzed using 
thSPSS version 20  Edition.
RESULTS
A total of 30 cases were reviewed. The age range of patients was between 16-70 years with a mean age of 43.5 years. 
Median age of 41.5 years. 83.4% of patients were female with remaining 16.7% males. The commonest tumor of 
origin was Breast Cancer (76.7%) followed by Lymphoma (6.7%),Lung (3.3%), Colon(3.3%), Endometrium(3.3%),  
Pancrease (3.3%),  Paranasal Sinus (3.3%). Majority of patients 73.3% received 30Gy in 10# over 2 weeks. Median 
Survival is 3 months. The most common clinical presentation is Headache (46.6%).
CONCLUSION 
Most Patients presented at advanced stages of their diseases. The mean age of patients that received Whole Brain 
Radiotherapy were in the fifth decade of life. More Females than Males received Whole Brain Radiotherapy.
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Study Design - The study was a retrospective review of 
patients treated with Whole Brain Radiotherapy for 
Brain Metastases between May 2006 and May 2015. 
Method-Patients with histologically confirmed 
systemic malignancy, Radiologically detected Brain 
Metastases and have received Whole Brain 
Radiotherapy were eligible for the study. Treatment 
files with incomplete data were excluded.
A Total number of 30 files were obtained. Data  were 
retrieved from the treatment files and supplemented 
by information from the case notes. Data collected  
included Age, Gender, Tumor of origin ,clinical 
presentation and Radiotherapy Regimen
Data Analysis –Data Analysis was done using 
Statistical Package for Social Sciences version 20
RESULTS
A Total of 30 cases were reviewed. The age range was 
between 16-70 years with a mean age of 43.5 years. 
Median age 41.5 years.83.4% of patients were female 
with remaining 16.7% males.The commonest tumor of 
origin was Breast (76.7%) followed by lymphoma 
(6.7%), Lung (3.3%), colon (3.3%), Endometrium 
(3.3%), Pancrease (3.3%), Paranasal Sinus (3.3%). 
Majority of Patients 73.3% received 30 Gy in 10 # over 2 
weeks. 13.3% received 15Gyin 5 # over weeks and 6.7% 
received 20Gy in 5 # over 1 week. Median Survival was 
3 months. The most frequent neurological symptom is 
Headache(46.6%).
Treatment of Brain Metastases is multidiscilplinary 
with radiation forming the cornerstone of treatment. It 
is a major component of treatment of cancer in African 
Countries providing effective palliative relief in 70-80% 
8,9of patients.
Although Whole Brain Radiotherapy is still a standard 
and active treatment in the management of Brain 
Metastases, trials of concurrent chemotherapy and 
Whole Brain Radiotherapy suggest  a significant 
increase in response rate especially for metastases from 
9lung cancer.
Chemotherapy maybe used as first line treatment in 
patients with Germ cell Tumor, Small cell Carcinoma, 
and Lymphoma. The response rate of brain Metastases 
to chemotherapy is similar to the response rate of the 
primary tumor and extracranial metastases with some 
10being more chemosensitive than others.
Supportive measures are often critical in improving 
patient outcome. They include treatment against 
vasogenic edema, pain and seizures. Because the 
management of Brain Metastases is palliative it is 
important to avoid any treatment that is useless or 
11harmful or has a poor toxicity efficacy ratio.
MATERIALS AND METHODS
Study Area - The study was conducted in the 
Department of Radiotherapy and Oncology of the 
Ahmadu Bello University Teaching Hospital Zaria. 
The center is situated in North Western Nigeria and 
serves as a referral center for patients within the region 
and across the country.
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TABLE 1.Distribution of Tumor of Origin and Age.
TABLE 2.Cross-tabulation of age and tumor of origin
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study where majority of patients were treated to 30GY 
in 10 Fractions over 2 weeks. The study by Edward et al 
however revealed that 81% 0f patients treated received 
1820Gy in 5# over 1 week. 
In the present study Females by far outnumber males, 
this could be attributed to the fact that majority of the 
patients that were treated for Brain Metastases had 
Breast Cancer which is more common in females than 
males. In a study by Olasode et al  32 (75%) of  the 48 
19 patients with brain metastases  were females. Similar 
results were also observed at a Radiotherapy Facility in 
13Lagos where 80% of Patients were females.  This 
however is in variance with Saha et al where most of the 
20patients were males .
According to studies done in Memorial-Kettering 
Cancer Center in New York by Victor TS and Takokura 
K, Ho SH et al in Tokyo, the most common primary 
producing Brain Metastases are Cancer of the Lung (40-
2150%) followed by Breast Cancer (15-25%).  These 
results are in contrast with this study where the most 
common primary tumor was breast cancer 76.7%, with 
Lung Cancer accounting for 3.3%.This is however in 
agreement with a study  at the Jos University Teaching 
Hospital Jos Plateau by G.O. Igun where the 
commonest origin of metastatic Brain tumor was 
22breast.
The Average Survival of Patients with Brain Metastases 
is typically less than 6 months, it is well recognized that 
subgroups of patients have significant probability of 
longer survival.  Median survival in this study was 3 
months in accordance with studies by Lang et al and 
Order et al that revealed median survival of 3-4 
23,24months.  According to Pearse, the median survival 
for unselected patients with Brain Metastases was 3-6 
25months. Tse Victor had a slightly lower median 
26   Survival of 2.3 Months.
Headache was the commonest clinical presentation in 
this study similar to what was recorded by Obajimi et al 
6at the University College Hospital Ibadan.
CONCLUSION
Breast Cancer is the most common tumor of origin in 
Patients receiving Whole brain radiotherapy for Brain 
Metastases with the mean age of presentation at 43.5 
years. Majority of Patients are females.30Gy in 10 # was 
the most common regimen received by Patients and the 
median survival for patients is 3 months.
Control of  Brain metastases remain challenging. 
Despite multimodal treatments, development of brain 
metastases  occur not only in patients who already 
have distant spread at diagnosis, but also in cancers 
that may be treated with a curative intent.
DISCUSSION
Findings from this Study revealed that majority (60%) 
rd thof patients were in the 3  and 4  decade of life, this is in 
accordance with the results of the University College 
rdHospital Ibadan where 82.4% of patients were in the 3  
th 1and 4  decade . According To Schouten et al,there is 
evidence of a lower incidence of Brain Metastases in the 
group of patients age >/ 70 this may reflect diagnostic 
bias, because it is likely that diagnostic work-up to 
detect Brain Metastases  probably will be less extensive 
12in older patients compared with younger patients.
The mean age of 43.5 years and Median Age of 41.5 is 
similar to the study by Popoola et al in Lagos with 
Mean and Median Age of  44 and 48 years 
13 respectively. The Mean Age of patients in a study in 
14Iran by  Ali et al was 53.6 years. The Mean age in the 
developing countries  is lower than that seen in 
developed  countries; Schackert et a and Wolf et al both 
showed a Mean Age of 67 and 60 years respectively in 
15,16Germany and the US.
Among 35 Radiotherapy centers evaluated in African 
countries, Brain Metastases were being treated by 
Radiotherapy to the Whole Brain to 30GY in 10 
Fractions either exclusively or in addition to the use of 
820GY in 5 Fractions . In the United Kingdom, the 
standard treatment is 30Gy in 10# or 20Gy in 5 # over2 
17weeks to the brain. This is in accordance with this 
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Treatment is palliative and Best supportive care 
remains the best option in patients with poor 
performance status (KPS <70), advanced non-cranial 
disease and a poor life expectancy.
There should be more concerted efforts in 
improvement of  palliative radiotherapy practises in 
the treatment of brain metastases. 
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